Prader-Willi syndrome (PWS) is a rare genetic disease that causes ... those genes are naturally silenced via a mechanism called imprinting. “For most of our genes, we inherit one copy from our father ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

People with Prader-Willi syndrome still carry the requisite genes from their mother, but those genes are naturally silenced in healthy people through a mechanism called imprinting. "There are many ...

The Food and Drug Administration on Wednesday approved the first medicine to treat people with Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat. The drug ...

"The FDA approval of Vykat XR is an incredible achievement for the entire PWS [Prader-Willi syndrome] community. I am excited to have Vykat XR available to help treat hyperphagia, which is the ...

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic disorder that causes excessive appetite and obesity. Vykat XR (diazoxide ...

"This approval is a testament to the power of persistence, science, and advocacy," said Susan Hedstrom, Executive Director of the Foundation for Prader-Willi Research. "For years, families and ...

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, making it the first treatment available for patients who experience feelings of ...